David A. Siegel Immunity Bio, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$2.68 - $6.14 $21,976 - $50,348
-8,200 Reduced 35.04%
15,200 $57,000
Q1 2022

May 16, 2022
SELL
$5.05 - $7.53 $23,735 - $35,391
-4,700 Reduced 16.73%
23,400 $131,000
Q4 2021

Feb 14, 2022
BUY
$5.67 - $10.18 $159,327 - $286,058
28,100 New
28,100 $171,000

Others Institutions Holding IBRX

# of Institutions
212
Shares Held
70.1M
Call Options Held
1.64M
Put Options Held
1.31M
View Full List

About ImmunityBio, Inc.

IBRX Quotes by TradingView
  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.35B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email